Trial Profile

A phase 2 study of oncolytic immunotherapy of metastatic neuroendocrine tumours using intralesional rose bengal disodium in combination with pembrolizumab

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 10 Sep 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

10 Sep 2019 New trial record
27 Aug 2019 According to a Provectus Biopharmaceuticals media release, design of this study was presented at the Australasian Gastro-Intestinal Trials Group (AGITG) Annual Scientific Meeting (ASM), and won AGITG ASMs Best of New Concepts Award.
27 Aug 2019 According to a Provectus Biopharmaceuticals media release, an efficacy assessment conducted 24 weeks after the initial treatment of the final patient in the initial group.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com